Latest Vitro Diagnostics (VODG) Headlines
Vitro Biopharma Products Advance Pancreatic Cancer Research
ACCESSWIRE - Tue Mar 11, 9:08AM CDT
Golden, Colorado / ACCESSWIRE / March 11, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that some of its products are being utilized in advancing pancreatic cancer research including development of new diagnostic tests and new therapeutic approaches. Pancreatic cancer remains one of the most deadly and least survivable cancers; it is asymptomatic until quite advanced and is resistant to conventional therapies. It has recently become apparent that cancer tumor cells are closely associated with other cells called cancer associated fibroblasts or CAFs. These cells promote the malignant process and block immune surveillance. CAFs are thus new drug targets for pancreatic and other cancer therapies. Vitro Biopharma products were used in recent research regarding pancreatic stellate cells, a CAF that is gaining considerable interest for new treatment options through advanced understanding of cancer biology.
10-K: VITRO DIAGNOSTICS INC
Edgar Online - Wed Feb 12, 3:26PM CST
ITEM 7.
Vitro Biopharma Revenues Increase in Early 2014: Plans Trials of Endogenous Stem Cell Activation for Therapeutic Benefit
ACCESSWIRE - Tue Feb 11, 9:19AM CST
Golden, Colorado / February 11, 2013 / ACCESSWIRE / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that its revenues increased substantially (78%, unaudited) in its first 2014 fiscal quarter due to its growing and expanding business relationship with Neuromics, Inc. Vitro Biopharma has now commercialized bio-analytical services as the initial stage in its expansion as a Contract Research Organization (CRO). The services now available include select and customized biomarker panel analysis providing customers quantitative levels of multiple biological molecules within various biological samples. The new business involves analysis of human serum samples collected from patients within a network of clinical treatment centers throughout central Europe. Our partner for these services is Joseph Smarta, Ph.D., a renowned immunologist who has orchestrated treatment of many patients suffering from a variety of diseases. While the analyses are for research purposes only, serial analysis of patients are provided to monitor status and indicate therapeutic effectiveness.
Vitro Biopharma's CEO Elaborates on Merger-Driven Growth Acceleration in an Interview with the Wall Street Analyst
ACCESSWIRE - Tue Nov 12, 10:31AM CST
Golden, Colorado - November 12, 2013 - Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced an interview of its CEO by Juan Costello of the Wall Street Analyst (http://thewallstreetanalyzer.com/vitro-diagnostics-otcbbvodg-ceo-interview). In the interview, our CEO elaborated on the effect of its planned merger with Neuromics, Inc. in greater detail and provided an overview of the near-term plans to accelerate growth. Completion of the merger would immediately expand revenues from research products by several-fold. While Vitro Biopharma's research products are primarily focused on adult stem cells and related products, the addition of Neuromics product lines expands our offerings to include antibodies, an expansive number of products for proteomics, apoptosis (cell death) assays, molecular biology reagents, together with numerous cell-based assay products complementary to Vitro's stem cell-based products.
Vitro Biopharma Announces Plans to Acquire and Merge with Neuromics, Inc.
ACCESSWIRE - Tue Oct 15, 1:22PM CDT
Golden, Colorado / October 15, 2013 / ACCESSWIRE / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, signed a non-binding letter of intent to acquire and merge with Neuromics, Inc, a privately held life-science firm located in Minneapolis, MN. The Merger would be structured as a reverse triangular merger, with Neuromics becoming a wholly-owned subsidiary of Vitro Biopharma. Completion of the proposed merger would reorganize Vitro Biopharma. to include significant expansion in its core product offerings, an improved balance sheet and a novel business model to accelerate growth. Accelerated revenue growth is envisioned through diversified sources including well-established sales to research & clinical development markets, unique stem cell-based assays for use in drug discovery, development and toxicology together with competitive stem cell-based therapies targeting emerging markets in regenerative medicine. The proposed strategic selling approach includes biopharmaceutical firms, large distributors and contract research organizations that would augment the growing and established incremental sales to global research laboratories.
Vitro Biopharma Expands its Product Lines While Targeting New Stem Cell Markets
ACCESSWIRE - Tue Sep 10, 7:00AM CDT
Golden, Colorado - (ACCESSWIRE - September 10, 2013) - Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced expansion of its current product lines and product development in additional market segments including drug discovery & development together with select opportunities within regenerative medicine market sectors. Vitro's present products target markets within stem cell and cancer research. We provide basic research tools including cell lines, cell culture media and assays of cellular function. We have recently added cancer-associated fibroblast cell lines and novel cell culture media formulations broadening our product offerings for research. Cancer-associated fibroblasts (CAFs) are non-tumor cells within cancerous tumors that promote tumor growth and metastasis.
OTC Daily Alert Stock Watch - Vitro Diagnostics, Inc. (OTCQB: VODG)
WorldStockWire - Thu Aug 29, 3:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Vitro Biopharma Appoints Established Life Science Sales Executive to Its Board of Directors
GlobeNewswire - Wed Feb 20, 12:25PM CST
Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, simultaneously accepted the resignation of Mr. Erik Van Horn from its Board of Directors and appointed Pete Shuster, the CEO of Neuromics, Inc. to its Board of Directors. Mr. Shuster is a seasoned and experienced sales executive. He is the current owner of Neuromics, Inc., a privately held and profitable business focused on sales of numerous (>2500) specialty life science products including stem cell products manufactured by Vitro Biopharma. Neuromics, Inc. sales have grown over 5.5-fold since inception in 2003. Shuster has extensive prior experience in managing sales of computer software and related products for companies including Caterpillar, Baxter Healthcare and Harley-Davidson.
Vitro Biopharma Inc announces commercial availability of MSC-derived human osteoblasts, leading to faster recovery of bone fractures
M2 - Wed Jan 23, 10:44AM CST
Stem cell company Vitro Diagnostics Inc (OTCQB:VODG) said on Tuesday that it has introduced a series of osteoblasts products to accelerate bone growth, fracture healing and development of new osteoporosis drugs.
Vitro Biopharma Launches New Stem Cell Products to Accelerate Bone Growth
GlobeNewswire - Tue Jan 22, 8:51AM CST
Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced the launch of a series of products with application to accelerated bone growth, fracture healing and development of new osteoporosis drugs. The new products are osteoblasts derived from human adult stem cells known as mesenchymal stem cells (MSCs). These cells lead to bone growth and function to maintain bone density and in the recovery from bone fractures. Osteoporosis, a disease characterized by reduction in bone density is thought to result from decreased osteoblast production by MSCs; bone growth necessary for repair of bone fractures also depends on osteoblasts. The new products include native and labeled MSC-derived human osteoblasts in various formats including fluorescent and magnetic cells for use in different imaging methods. For example, magnetic osteoblast cells labeled with super paramagnetic iron oxide (SPIO) may be used for in-vivo imaging of osteoblasts using magnetic resonance imaging (MRI) a common clinical imaging proced
Vitro Biopharma Products Advance Pancreatic Cancer Research
ACCESSWIRE - Tue Mar 11, 9:08AM CDT
Golden, Colorado / ACCESSWIRE / March 11, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that some of its products are being utilized in advancing pancreatic cancer research including development of new diagnostic tests and new therapeutic approaches. Pancreatic cancer remains one of the most deadly and least survivable cancers; it is asymptomatic until quite advanced and is resistant to conventional therapies. It has recently become apparent that cancer tumor cells are closely associated with other cells called cancer associated fibroblasts or CAFs. These cells promote the malignant process and block immune surveillance. CAFs are thus new drug targets for pancreatic and other cancer therapies. Vitro Biopharma products were used in recent research regarding pancreatic stellate cells, a CAF that is gaining considerable interest for new treatment options through advanced understanding of cancer biology.
10-K: VITRO DIAGNOSTICS INC
Edgar Online - Wed Feb 12, 3:26PM CST
ITEM 7.
Vitro Biopharma Revenues Increase in Early 2014: Plans Trials of Endogenous Stem Cell Activation for Therapeutic Benefit
ACCESSWIRE - Tue Feb 11, 9:19AM CST
Golden, Colorado / February 11, 2013 / ACCESSWIRE / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that its revenues increased substantially (78%, unaudited) in its first 2014 fiscal quarter due to its growing and expanding business relationship with Neuromics, Inc. Vitro Biopharma has now commercialized bio-analytical services as the initial stage in its expansion as a Contract Research Organization (CRO). The services now available include select and customized biomarker panel analysis providing customers quantitative levels of multiple biological molecules within various biological samples. The new business involves analysis of human serum samples collected from patients within a network of clinical treatment centers throughout central Europe. Our partner for these services is Joseph Smarta, Ph.D., a renowned immunologist who has orchestrated treatment of many patients suffering from a variety of diseases. While the analyses are for research purposes only, serial analysis of patients are provided to monitor status and indicate therapeutic effectiveness.
Vitro Biopharma's CEO Elaborates on Merger-Driven Growth Acceleration in an Interview with the Wall Street Analyst
ACCESSWIRE - Tue Nov 12, 10:31AM CST
Golden, Colorado - November 12, 2013 - Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced an interview of its CEO by Juan Costello of the Wall Street Analyst (http://thewallstreetanalyzer.com/vitro-diagnostics-otcbbvodg-ceo-interview). In the interview, our CEO elaborated on the effect of its planned merger with Neuromics, Inc. in greater detail and provided an overview of the near-term plans to accelerate growth. Completion of the merger would immediately expand revenues from research products by several-fold. While Vitro Biopharma's research products are primarily focused on adult stem cells and related products, the addition of Neuromics product lines expands our offerings to include antibodies, an expansive number of products for proteomics, apoptosis (cell death) assays, molecular biology reagents, together with numerous cell-based assay products complementary to Vitro's stem cell-based products.
Vitro Biopharma Announces Plans to Acquire and Merge with Neuromics, Inc.
ACCESSWIRE - Tue Oct 15, 1:22PM CDT
Golden, Colorado / October 15, 2013 / ACCESSWIRE / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, signed a non-binding letter of intent to acquire and merge with Neuromics, Inc, a privately held life-science firm located in Minneapolis, MN. The Merger would be structured as a reverse triangular merger, with Neuromics becoming a wholly-owned subsidiary of Vitro Biopharma. Completion of the proposed merger would reorganize Vitro Biopharma. to include significant expansion in its core product offerings, an improved balance sheet and a novel business model to accelerate growth. Accelerated revenue growth is envisioned through diversified sources including well-established sales to research & clinical development markets, unique stem cell-based assays for use in drug discovery, development and toxicology together with competitive stem cell-based therapies targeting emerging markets in regenerative medicine. The proposed strategic selling approach includes biopharmaceutical firms, large distributors and contract research organizations that would augment the growing and established incremental sales to global research laboratories.
Vitro Biopharma Expands its Product Lines While Targeting New Stem Cell Markets
ACCESSWIRE - Tue Sep 10, 7:00AM CDT
Golden, Colorado - (ACCESSWIRE - September 10, 2013) - Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced expansion of its current product lines and product development in additional market segments including drug discovery & development together with select opportunities within regenerative medicine market sectors. Vitro's present products target markets within stem cell and cancer research. We provide basic research tools including cell lines, cell culture media and assays of cellular function. We have recently added cancer-associated fibroblast cell lines and novel cell culture media formulations broadening our product offerings for research. Cancer-associated fibroblasts (CAFs) are non-tumor cells within cancerous tumors that promote tumor growth and metastasis.
OTC Daily Alert Stock Watch - Vitro Diagnostics, Inc. (OTCQB: VODG)
WorldStockWire - Thu Aug 29, 3:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Vitro Biopharma Appoints Established Life Science Sales Executive to Its Board of Directors
GlobeNewswire - Wed Feb 20, 12:25PM CST
Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, simultaneously accepted the resignation of Mr. Erik Van Horn from its Board of Directors and appointed Pete Shuster, the CEO of Neuromics, Inc. to its Board of Directors. Mr. Shuster is a seasoned and experienced sales executive. He is the current owner of Neuromics, Inc., a privately held and profitable business focused on sales of numerous (>2500) specialty life science products including stem cell products manufactured by Vitro Biopharma. Neuromics, Inc. sales have grown over 5.5-fold since inception in 2003. Shuster has extensive prior experience in managing sales of computer software and related products for companies including Caterpillar, Baxter Healthcare and Harley-Davidson.
Vitro Biopharma Inc announces commercial availability of MSC-derived human osteoblasts, leading to faster recovery of bone fractures
M2 - Wed Jan 23, 10:44AM CST
Stem cell company Vitro Diagnostics Inc (OTCQB:VODG) said on Tuesday that it has introduced a series of osteoblasts products to accelerate bone growth, fracture healing and development of new osteoporosis drugs.
Vitro Biopharma Launches New Stem Cell Products to Accelerate Bone Growth
GlobeNewswire - Tue Jan 22, 8:51AM CST
Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced the launch of a series of products with application to accelerated bone growth, fracture healing and development of new osteoporosis drugs. The new products are osteoblasts derived from human adult stem cells known as mesenchymal stem cells (MSCs). These cells lead to bone growth and function to maintain bone density and in the recovery from bone fractures. Osteoporosis, a disease characterized by reduction in bone density is thought to result from decreased osteoblast production by MSCs; bone growth necessary for repair of bone fractures also depends on osteoblasts. The new products include native and labeled MSC-derived human osteoblasts in various formats including fluorescent and magnetic cells for use in different imaging methods. For example, magnetic osteoblast cells labeled with super paramagnetic iron oxide (SPIO) may be used for in-vivo imaging of osteoblasts using magnetic resonance imaging (MRI) a common clinical imaging proced
